Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Rhea-AI Summary

Know Labs, Inc. (KNW) will present updated clinical research results and developments of its non-invasive blood glucose monitor at the International Fair of New Technologies in Diabetes. The company will share updates on the latest developments of its non-invasive blood glucose monitor and present results from its ongoing clinical research, with two abstracts accepted for e-poster presentation in the scientific program. Dr. Virend K. Somers of the Mayo Clinic will present the results from the current clinical research protocol, assessing the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference. Know Labs will also sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) during the conference to discuss non-invasive glucose monitoring innovation.

The Company to present updated clinical research results and developments of its non-invasive blood glucose monitor

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024.

The Company will share updates on the latest developments of its non-invasive blood glucose monitor and present results from its ongoing clinical research, with two abstracts accepted for e-poster presentation in the scientific program. These results will be presented by Dr. Virend K. Somers of the Mayo Clinic, who serves as an author and co-investigator on Know Labs’ current clinical research protocol. The protocol assesses the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference.

During the conference Know Labs will sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) where key thought leaders in the diabetes management field will discuss non-invasive glucose monitoring innovation.

For more information on Know Labs, visit www.knowlabs.co.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240123862937/en/

For Know Labs Media Inquiries:

Matter Health

Abby Mayo

Knowlabs@matternow.com

Ph. (617) 272-0592

Know Labs, Inc.:

Jordyn Hujar

jordyn@knowlabs.co

Ph. (206) 629-6414

Source: Know Labs, Inc.

FAQ

What will Know Labs present at the International Fair of New Technologies in Diabetes?

Know Labs will present updated clinical research results and developments of its non-invasive blood glucose monitor.

Where will the International Fair of New Technologies in Diabetes take place?

The fair will take place at the 17th International Conference on Advanced Technologies & Treatments for Diabetes in Florence, Italy.

Who will present the results from the current clinical research protocol at the conference?

Dr. Virend K. Somers of the Mayo Clinic will present the results.

What is the purpose of the clinical research protocol?

The protocol assesses the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference.

What event will Know Labs sponsor during the conference?

Know Labs will sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) to discuss non-invasive glucose monitoring innovation.